JP2017528475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528475A5 JP2017528475A5 JP2017513759A JP2017513759A JP2017528475A5 JP 2017528475 A5 JP2017528475 A5 JP 2017528475A5 JP 2017513759 A JP2017513759 A JP 2017513759A JP 2017513759 A JP2017513759 A JP 2017513759A JP 2017528475 A5 JP2017528475 A5 JP 2017528475A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cancer
- compound according
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims 2
- ZMLHBBXPXZXTSP-UHFFFAOYSA-N 2-fluoropropane Chemical group C[C](C)F ZMLHBBXPXZXTSP-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 101700007719 RAF1 Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 101710030209 lin-45 Proteins 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 101700004551 BRAF Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 Ifosfamide Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
Claims (14)
- 下記式Ia:
R1は、水素およびメチルから選択され、
R2は、ピリジニルおよびフェニルから選択され、ここで、フェニルまたはピリジニルは、トリフルオロメチル、1,1−ジフルオロエチルおよび2−フルオロプロパン−2−イルから選択される基により置換されていてよく、
R3は、水素およびOHから選択され、
R4は、2−(ホスホノオキシ)メチルおよびホスホノオキシから選択され、
Zは、NおよびCHから選択される)
の化合物または薬学的に許容されるその塩。 -
- 下記式Ib:
R1は、水素およびメチルから選択され、
R2は、ピリジニルおよびフェニルから選択され、ここで、フェニルまたはピリジニルは、トリフルオロメチル、1,1−ジフルオロエチルおよび2−フルオロプロパン−2−イルから選択される基により置換されていてよく、
R3は、水素であり、
R4は、ホスホノオキシであり、
Zは、NおよびCHから選択される)
の化合物または薬学的に許容されるその塩。 -
- 次式:
- 請求項1〜5のいずれか1項に記載の化合物または薬学的に許容されるその塩、および1種または複数の薬学的に許容される担体を含む、医薬組成物。
- 治療有効量の請求項1〜5のいずれか1項に記載の化合物または薬学的に許容されるその塩、および1種または複数の治療上活性な共剤を含む、組合せ。
- 前記治療上活性な共剤が、PI3Kの阻害剤、Raf経路の他の阻害剤、パクリタキセル、ドセタキセル、テモゾロミド、白金化合物、ドキソルビシン、ビンブラスチン、シクロホスファミド、トポテカン、ゲムシタビン、イホスファミド、エトポシド、およびイリノテカンから選択されるものである、請求項7に記載の組合せ。
- 医薬として使用するための、請求項1〜5のいずれか1項に記載の化合物または薬学的に許容されるその塩。
- がんの処置において使用するための、請求項9に記載の化合物または薬学的に許容されるその塩。
- 前記がんが、固形腫瘍、黒色腫、乳がん、肺がん、肝臓がん、肉腫、GI腫瘍、卵巣がん、大腸結腸がん、甲状腺がん、および膵臓がんから選択されるものである、請求項10に記載の化合物または薬学的に許容されるその塩。
- 前記がんが、卵巣がん、非小細胞肺がん、およびRas変異によって推進されるがんから選択されるものである、請求項10に記載の化合物または薬学的に許容されるその塩。
- Rafの過度のまたは望ましくない活性レベルを特徴とする状態の処置において使用するための、請求項1〜5のいずれか1項に記載の化合物または薬学的に許容されるその塩。
- 前記状態が、B−Rafおよび/またはC−Rafの過度のもしくは望ましくない活性レベルを特徴とする状態である、請求項13に記載の化合物または薬学的に許容されるその塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049469P | 2014-09-12 | 2014-09-12 | |
US62/049,469 | 2014-09-12 | ||
PCT/IB2015/056986 WO2016038581A1 (en) | 2014-09-12 | 2015-09-11 | Compounds and compositions as raf kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017528475A JP2017528475A (ja) | 2017-09-28 |
JP2017528475A5 true JP2017528475A5 (ja) | 2018-10-18 |
JP6678655B2 JP6678655B2 (ja) | 2020-04-08 |
Family
ID=54148595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017513759A Active JP6678655B2 (ja) | 2014-09-12 | 2015-09-11 | Rafキナーゼ阻害剤としての化合物および組成物 |
Country Status (30)
Country | Link |
---|---|
US (2) | US9573969B2 (ja) |
EP (1) | EP3191472B1 (ja) |
JP (1) | JP6678655B2 (ja) |
KR (1) | KR20170053686A (ja) |
CN (1) | CN107108671B (ja) |
AP (1) | AP2017009830A0 (ja) |
AR (1) | AR101815A1 (ja) |
AU (1) | AU2015313782B2 (ja) |
BR (1) | BR112017004741A2 (ja) |
CA (1) | CA2960971A1 (ja) |
CL (1) | CL2017000541A1 (ja) |
CO (1) | CO2017002292A2 (ja) |
CR (1) | CR20170092A (ja) |
CU (1) | CU20170026A7 (ja) |
DO (1) | DOP2017000066A (ja) |
EA (1) | EA031061B1 (ja) |
EC (1) | ECSP17021897A (ja) |
ES (1) | ES2729243T3 (ja) |
IL (1) | IL250950A0 (ja) |
MX (1) | MX2017003233A (ja) |
NI (1) | NI201700029A (ja) |
PE (1) | PE20171338A1 (ja) |
PH (1) | PH12017500416A1 (ja) |
SG (1) | SG11201701734QA (ja) |
SV (1) | SV2017005405A (ja) |
TN (1) | TN2017000075A1 (ja) |
TW (1) | TWI603977B (ja) |
UY (1) | UY36294A (ja) |
WO (1) | WO2016038581A1 (ja) |
ZA (1) | ZA201701633B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ710034A (en) | 2013-03-14 | 2020-06-26 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
BR112016016289B1 (pt) * | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | Heteroaris e usos dos mesmos |
DK3191487T3 (da) | 2014-09-12 | 2019-10-28 | Boehringer Ingelheim Int | Spirocykliske cathepsin-c-inhibitorer |
UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
JOP20200014A1 (ar) * | 2017-08-03 | 2022-10-30 | Novartis Ag | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf |
JP2022525885A (ja) * | 2019-03-22 | 2022-05-20 | キネート バイオファーマ インク. | Rafキナーゼの阻害剤 |
AR118826A1 (es) | 2019-05-03 | 2021-11-03 | Kinnate Biopharma Inc | Inhibidores de cinasas raf |
BR112022007612A2 (pt) * | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
JP2024517431A (ja) * | 2021-04-23 | 2024-04-22 | キネート バイオファーマ インク. | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
EP4326256A1 (en) | 2021-04-23 | 2024-02-28 | Kinnate Biopharma Inc. | Treatment of cancer with a raf inhibitor |
AU2022274298A1 (en) * | 2021-05-12 | 2023-09-28 | Boehringer Ingelheim International Gmbh | Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
DE3486009T2 (de) | 1983-09-09 | 1993-04-15 | Takeda Chemical Industries Ltd | 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung. |
JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
JP2808460B2 (ja) | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
ES2384551T3 (es) | 1997-03-05 | 2012-07-06 | Sugen, Inc. | Formulaciones para agentes farmacéuticos hidrófobos |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
IL144910A0 (en) | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
US6310574B1 (en) | 1999-08-05 | 2001-10-30 | Vega Grieshaber Kg | Level transmitter |
ATE339406T1 (de) | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
MXPA02005106A (es) | 1999-11-22 | 2002-11-07 | Smithkline Beecham Plc | Compuestos novedosos. |
BR0107713A (pt) | 2000-01-18 | 2002-11-19 | Vertex Pharma | Inibidores de girase e usos dos mesmos |
AU2001232809A1 (en) | 2000-01-18 | 2001-07-31 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
WO2001066539A1 (en) | 2000-03-06 | 2001-09-13 | Smithkline Beecham P.L.C. | Imidazol derivatives as raf kinase inhibitors |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
AU2001244618A1 (en) | 2000-03-30 | 2001-10-15 | Takeda Chemical Industries Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
EP2177520A1 (en) | 2000-06-12 | 2010-04-21 | Eisai R&D Management Co., Ltd. | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors |
EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
JP4217480B2 (ja) | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
JP4267920B2 (ja) | 2001-01-26 | 2009-05-27 | 中外製薬株式会社 | 代謝調節剤として有用なマロニル−CoA脱炭酸酵素阻害剤 |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
NZ535985A (en) | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
ES2323421T3 (es) | 2002-09-18 | 2009-07-15 | Pfizer Products Inc. | Nuevos compuestos de oxazol como inhibidores del factor de crecimientotransformador (tgf). |
EA200500378A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf) |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
CN1863774B (zh) | 2003-10-08 | 2010-12-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
EP1682126B1 (en) | 2003-10-16 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Substituted benzazoles and use thereof as inhibitors of raf kinase |
JP5095216B2 (ja) | 2003-11-14 | 2012-12-12 | ローラス セラピューティクス インコーポレーテッド | アリールイミダゾールおよびその抗癌剤としての使用 |
US7678810B2 (en) | 2004-03-05 | 2010-03-16 | Taisho Pharmaceutical Co., Ltd | Thiazole derivative |
KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
AU2005280168A1 (en) | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylimidazoles as TGF-beta inhibitors |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
JP2007246520A (ja) | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Rage阻害剤 |
US8217037B2 (en) | 2006-04-07 | 2012-07-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
AU2008269516B2 (en) | 2007-06-27 | 2011-11-17 | Astrazeneca Ab | Pyrazinone derivatives and their use in the treatment of lung diseases |
CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
US7968536B2 (en) | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
US20100240657A1 (en) | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
JP2010533159A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物947 |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP5241834B2 (ja) | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
WO2009030952A2 (en) | 2007-09-05 | 2009-03-12 | Astrazeneca Ab | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway |
WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
US8129394B2 (en) | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
CN102089278A (zh) | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
EA019722B1 (ru) | 2008-07-24 | 2014-05-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
AU2009334997A1 (en) * | 2008-12-30 | 2011-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as Raf kinase inhibitors |
EP2470532A1 (en) * | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
CN102471310A (zh) | 2009-09-04 | 2012-05-23 | 诺瓦提斯公司 | 用于治疗增生性疾病的联吡啶化合物 |
WO2011059610A1 (en) | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
NZ600837A (en) | 2009-12-28 | 2014-01-31 | Gen Inc Ass Pharma Valley Project Supporting Organization | 1,3,4-oxadiazole-2-carboxamide compound |
KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
CA2803055A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
CN101993415B (zh) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
AU2012302042B2 (en) | 2011-09-01 | 2016-03-31 | Novartis Ag | Compounds and compositions as c-kit kinase inhibitors |
CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
CN104379574B (zh) | 2012-05-15 | 2017-03-01 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
AR091654A1 (es) | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-10 UY UY0001036294A patent/UY36294A/es not_active Application Discontinuation
- 2015-09-11 AU AU2015313782A patent/AU2015313782B2/en not_active Ceased
- 2015-09-11 US US14/851,249 patent/US9573969B2/en active Active
- 2015-09-11 JP JP2017513759A patent/JP6678655B2/ja active Active
- 2015-09-11 TW TW104130161A patent/TWI603977B/zh not_active IP Right Cessation
- 2015-09-11 PE PE2017000445A patent/PE20171338A1/es not_active Application Discontinuation
- 2015-09-11 AR ARP150102898A patent/AR101815A1/es unknown
- 2015-09-11 TN TN2017000075A patent/TN2017000075A1/en unknown
- 2015-09-11 CU CUP2017000026A patent/CU20170026A7/es unknown
- 2015-09-11 BR BR112017004741A patent/BR112017004741A2/pt not_active IP Right Cessation
- 2015-09-11 CA CA2960971A patent/CA2960971A1/en not_active Abandoned
- 2015-09-11 CN CN201580061323.4A patent/CN107108671B/zh active Active
- 2015-09-11 EP EP15766660.3A patent/EP3191472B1/en active Active
- 2015-09-11 ES ES15766660T patent/ES2729243T3/es active Active
- 2015-09-11 MX MX2017003233A patent/MX2017003233A/es unknown
- 2015-09-11 SG SG11201701734QA patent/SG11201701734QA/en unknown
- 2015-09-11 WO PCT/IB2015/056986 patent/WO2016038581A1/en active Application Filing
- 2015-09-11 CR CR20170092A patent/CR20170092A/es unknown
- 2015-09-11 EA EA201790599A patent/EA031061B1/ru not_active IP Right Cessation
- 2015-09-11 AP AP2017009830A patent/AP2017009830A0/en unknown
- 2015-09-11 KR KR1020177009468A patent/KR20170053686A/ko unknown
-
2017
- 2017-01-04 US US15/397,787 patent/US9809610B2/en active Active
- 2017-03-05 IL IL250950A patent/IL250950A0/en unknown
- 2017-03-06 PH PH12017500416A patent/PH12017500416A1/en unknown
- 2017-03-07 ZA ZA2017/01633A patent/ZA201701633B/en unknown
- 2017-03-07 CL CL2017000541A patent/CL2017000541A1/es unknown
- 2017-03-08 CO CONC2017/0002292A patent/CO2017002292A2/es unknown
- 2017-03-09 DO DO2017000066A patent/DOP2017000066A/es unknown
- 2017-03-10 NI NI201700029A patent/NI201700029A/es unknown
- 2017-03-10 SV SV2017005405A patent/SV2017005405A/es unknown
- 2017-04-07 EC ECIEPI201721897A patent/ECSP17021897A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017528475A5 (ja) | ||
RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
PE20171338A1 (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
JP2016006118A5 (ja) | ||
JP2013535491A5 (ja) | ||
MX2016006119A (es) | Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[( 3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer. | |
EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
JP2014508811A5 (ja) | ||
JP2016515561A5 (ja) | ||
GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
JP2015533176A5 (ja) | ||
JP2016525097A5 (ja) | ||
JP2013507415A5 (ja) | ||
TN2012000609A1 (en) | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | |
MY180618A (en) | Pyridazinone compounds and their use as daao inhibitors | |
JP2017514809A5 (ja) | ||
UA107675C2 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
JP2015512943A5 (ja) | ||
MX2014000635A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak. | |
EA201791585A1 (ru) | Способ и композиции для ингибирования миграции клеток опухоли и образования метастазов | |
JP2017535601A5 (ja) |